Suppr超能文献

他莫昔芬通过氧化应激调节雌激素受体阴性乳腺癌细胞中的蛋白激酶C。

Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells.

作者信息

Gundimeda U, Chen Z H, Gopalakrishna R

机构信息

Department of Cell and Neurobiology, School of Medicine, University of Southern California, Los Angeles, California 90033, USA.

出版信息

J Biol Chem. 1996 Jun 7;271(23):13504-14. doi: 10.1074/jbc.271.23.13504.

Abstract

Nonsteroidal agent tamoxifen (Tam), a therapeutic/chemopreventive agent for breast cancer, inhibits protein kinase C (PKC), which is considered to be one of its extra-estrogen receptor sites of action. This drug is required at higher (>100 microM) concentrations to inhibit PKC in the test tube, whereas it is required at lower (1-10 microM) concentrations to induce inhibition of cell growth in estrogen receptor-negative cell types. To identify additional mechanisms of action of Tam on PKC and cell growth, studies with MDA-MB-231, an estrogen receptor-negative breast carcinoma cell type, have been carried out. Upon treatment with 5-20 microM Tam, a cytosol to membrane translocation of PKC occurred within 30 min, which was then followed by a down-regulation of the enzyme within 2 h. A transient generation of Ca2+/lipid-independent activated form of PKC was observed during this period. Rapidly growing cells require nearly 2-3-fold lower concentrations (2-5 microM) of Tam than do confluent cells to induce changes in PKC. Furthermore, phorbol ester binding observed with intact cells also decreased in Tam-treated cells only under the conditions PKC was inactivated. Unlike phorbol esters, Tam did not directly support the membrane association of PKC. The release of arachidonic acid correlated with the PKC membrane translocation. Studies carried out with [3H]Tam revealed that Tam partitioned into the membrane, and there was no appreciable covalent association of [3H]Tam with cellular proteins within this limited time period (2 h). Various antioxidants (vitamin E, vitamin C, beta-carotene, catalase, and superoxide dismutase) inhibited all these cellular effects of Tam. Moreover, vitamin E strikingly blocked Tam-induced growth inhibition. To determine whether oxymetabolites of Tam can affect PKC permanently, OH-Tam was tested with purified PKC. In contrast to Tam, which reversibly inhibited PKC, OH-Tam permanently inactivated the enzyme by modifying the catalytic domain at lower concentrations. The vicinal thiols present within this domain were found to be required to induce this inactivation. This effect was partially blocked by various antioxidants. This is the first report showing the role of oxidative stress in mediating the actions of Tam. Taken together these results suggest that Tam, by initially partitioning into the membranes, induces a generation of transmembrane signals and an oxidative stress to elicit the membrane association of PKC, followed by an irreversible activation, and subsequent down-regulation of this enzyme, which, in part, may lead to cell growth inhibition.

摘要

非甾体类药物他莫昔芬(Tam)是一种用于乳腺癌治疗/化学预防的药物,它能够抑制蛋白激酶C(PKC),PKC被认为是其雌激素受体外的作用位点之一。在试管中,该药物需要较高浓度(>100微摩尔)才能抑制PKC,而在雌激素受体阴性细胞类型中,诱导细胞生长抑制则需要较低浓度(1 - 10微摩尔)。为了确定他莫昔芬对PKC和细胞生长作用的其他机制,我们对雌激素受体阴性乳腺癌细胞系MDA - MB - 231进行了研究。用5 - 20微摩尔的他莫昔芬处理后,30分钟内PKC发生了从胞质溶胶到细胞膜的转位,随后在2小时内该酶表达下调。在此期间观察到PKC短暂生成了与钙/脂质无关的活化形式。与汇合细胞相比,快速生长的细胞诱导PKC变化所需的他莫昔芬浓度要低近2 - 3倍(2 - 5微摩尔)。此外,只有在PKC失活的条件下,他莫昔芬处理的细胞中观察到的佛波酯结合才会减少。与佛波酯不同,他莫昔芬并不直接支持PKC与膜的结合。花生四烯酸的释放与PKC的膜转位相关。用[³H]他莫昔芬进行的研究表明,他莫昔芬会分配到细胞膜中,并且在这个有限的时间段(2小时)内,[³H]他莫昔芬与细胞蛋白没有明显的共价结合。各种抗氧化剂(维生素E、维生素C、β - 胡萝卜素、过氧化氢酶和超氧化物歧化酶)抑制了他莫昔芬的所有这些细胞效应。此外,维生素E显著阻断了他莫昔芬诱导的生长抑制。为了确定他莫昔芬的氧化代谢产物是否能永久影响PKC,我们用纯化的PKC对羟基他莫昔芬(OH - Tam)进行了测试。与可逆抑制PKC的他莫昔芬不同,OH - Tam在较低浓度下通过修饰催化结构域使该酶永久失活。发现该结构域中的邻位硫醇是诱导这种失活所必需的。这种效应被各种抗氧化剂部分阻断。这是第一份显示氧化应激在介导他莫昔芬作用中作用的报告。综上所述,这些结果表明,他莫昔芬最初通过分配到细胞膜中,诱导跨膜信号的产生和氧化应激,从而引发PKC与膜的结合,随后是该酶的不可逆激活和随后的下调,这可能部分导致细胞生长抑制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验